Johnson & Johnson recently published the transcript of their second-quarter 2025 earnings conference call, held on July 16, 2025. The event was attended by key figures from the company, including Chairman and CEO Joaquin Duato, Chief Financial Officer Joseph Wolk, and various Executive Vice Presidents from different divisions. During the call, management highlighted the strength of their diversified business and projected elevated growth in the second half of the year. They discussed anticipated approvals and submissions in critical areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular treatments. These developments are expected to "extend and improve lives in transformative ways and deliver significant value to patients and shareholders." The call was led by Darren Snellgrove, Vice President of Investor Relations, who emphasized the company's optimistic outlook and strategic advancements. The company encouraged listeners to stay informed about their progress and future announcements. The full transcript can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.